Glucotrack, Inc. 8-K

What Happened

• Glucotrack, Inc. (GCTK) filed an 8-K reporting that Nasdaq staff notified the company on May 11, 2026 that it no longer met Rule 5550(a)(2)’s $1.00 minimum bid-price requirement and had determined to delist the company's securities.
• On May 15, 2026 Nasdaq sent a second letter saying the company’s Form 10‑Q for the quarter ended March 31, 2026 shows it no longer meets the $2,500,000 minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), creating an additional basis for delisting.
• The company intends to request a hearing before a Nasdaq Hearings Panel by May 18, 2026 to appeal; a timely hearing request will stay delisting actions while the process unfolds. The company plans to present a compliance plan at the hearing but warned there is no assurance of a successful outcome.

Key Details

• Nasdaq Rule cited: 5550(a)(2) — minimum bid price requirement of $1.00 per share.
• Additional deficiency: Listing Rule 5550(b)(1) — minimum stockholders’ equity requirement of $2,500,000.
• Relevant dates: May 11, 2026 (staff determination on bid price); May 15, 2026 (additional notice regarding Form 10‑Q); hearing request deadline May 18, 2026.
• Triggering filing: Form 10‑Q for period ended March 31, 2026 indicated equity deficiency.

Why It Matters

• The notice starts Nasdaq’s delisting process for Glucotrack based on bid price and equity shortfalls. The company’s timely hearing request pauses delisting while it appeals and presents a remediation plan.
• The filing states there is no assurance the appeal will succeed or that the company can regain/maintain compliance. For investors, an adverse outcome could affect the stock’s listing status, liquidity, and visibility—matters that can influence trading and the company’s access to capital.